Pharmacological management of cerebral ischemia in the elderly

Expert Opin Pharmacother. 2021 May;22(7):897-906. doi: 10.1080/14656566.2020.1856815. Epub 2020 Dec 31.

Abstract

Introduction: For elderly adults in the United States, stroke is the fifth leading cause of death of which ischemic strokes comprise a vast majority. Optimal pharmacological management of elderly ischemic stroke patients involves both reperfusion and supportive care. Recent research into pharmacological management has focused on vascular, immunomodulatory, cytoprotective, and alternative agents, some of which have shown limited success in clinical trials. However, no treatments have been established as a reliable mode for management of cerebral ischemia for elderly adults beyond acute thrombolysis.Areas covered: The authors conducted a literature search for ischemic stroke management in the elderly and a search for human drug studies for managing ischemic stroke on clinicaltrials.gov. Here, they describe recent progress in the pharmacological management of cerebral ischemia in the elderly.Expert opinion: Many drug classes (antihypertensive, cytoprotective and immunomodulatory, and alternative agents) have been explored with limited success in managing ischemic stroke, though some have shown preventative benefits. We generally observed a broad gap in evidence on elderly patients from studies across all drug classes, necessitating further studies to gain an understanding of effective management of ischemic stroke in this large demographic of patients.

Keywords: Antihypertensive; antiplatelet; cytoprotective; elderly; immunomodulatory; ischemia; management; pharmacology; stroke; thrombolytic.

MeSH terms

  • Aged
  • Brain Ischemia* / drug therapy
  • Cerebral Infarction / drug therapy
  • Fibrinolytic Agents / therapeutic use
  • Humans
  • Stroke* / drug therapy
  • Thrombolytic Therapy

Substances

  • Fibrinolytic Agents